<DOC>
	<DOCNO>NCT00040937</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth cancer cell stop blood flow cancer . Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . Giving thalidomide peripheral stem cell transplant may effective treat newly diagnose multiple myeloma . PURPOSE : This phase II trial study well give thalidomide chemotherapy peripheral stem cell transplant work treat patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>S0204 Thalidomide , Chemotherapy , Peripheral Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy toxicity thalidomide dexamethasone pre-transplantation induction regimen patient multiple myeloma . - Determine , preliminarily , safety efficacy prednisone thalidomide maintenance therapy patient . - Correlate chromosome 13 abnormality therapeutic response patient treat regimen . - Correlate specific subsets chromosome aberration event-free overall survival patient treat regimen . - Evaluate immune reconstitution recovery first second transplantation patient . OUTLINE : This multicenter study . - Induction chemotherapy : Patients receive oral thalidomide daily day 1-35 oral dexamethasone daily day 1-4 , 9-12 , 17-20 . Treatment repeat every 35 day 3 course absence disease progression unacceptable toxicity . - Stem cell mobilization collection : Beginning 5-7 day , 3 week , completion induction chemotherapy , patient receive cyclophosphamide IV 45-60 minute day 0 , filgrastim ( G-CSF ) subcutaneously ( SC ) day 1-10 , sargramostim ( GM-CSF ) SC begin day 1 continue completion peripheral blood stem cell ( PBSC ) collection . Patients begin PBSC collection day 11 soon blood count recover . - First transplantation : Within 3-6 week cyclophosphamide administration , patient receive melphalan IV 20 minute day -1 . Patients undergo PBSC infusion day 0 . Patients receive GM-CSF SC IV begin day 6 continue blood count recover . - Second transplantation : Between 2-4 month first transplantation , patient undergo second tandem melphalan PBSC transplantation GM-CSF support . - Maintenance therapy : Beginning 70-90 day post-transplantation , patient receive oral prednisone every day oral thalidomide daily . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 12 month 10 year . PROJECTED ACCRUAL : Approximately 99 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose multiple myeloma require treatment Smoldering myeloma evidence progressive disease require chemotherapy More 25 % increase M component level and/or BenceJones excretion symptom development Nonsecretory patient least 30 % bone marrow plasmacytosis No IgM peak unless evidence 30 % bone marrow plasmacytosis 3 lytic lesion PATIENT CHARACTERISTICS : Age 18 65 Performance status Zubrod 02 OR Zubrod 34 base solely bone pain Life expectancy Not specify Hematopoietic No untreated , unresolved symptomatic hyperviscosity Hepatic Hepatitis B negative Renal Creatinine great 3 mg/dL renal failure dialysis ( hydration and/or correction hypercalcemia ) Cardiovascular No history chronic cerebrovascular accident No myocardial infarction within past 6 month No unstable angina No congestive heart failure difficult control No uncontrollable hypertension No cardiac arrhythmia difficult control Pulmonary No history chronic obstructive chronic restrictive pulmonary disease No untreated , unresolved pneumonia Pulmonary function test ( PFTs ) least 50 % predict DLCO least 50 % predict Arterial partial pressure oxygen great 70 unable complete PFTs due bone pain fracture Other HIV negative No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No untreated , unresolved pathologic fracture Not pregnant nursing Negative pregnancy test Fertile patient must use least 2 highly effective method contraception 4 week , , least 4 week study participation PRIOR CONCURRENT THERAPY : Biologic therapy No 8 week prior thalidomide therapy Chemotherapy No prior chemotherapy disease Endocrine therapy Prior steroid therapy allow provide treatment duration 2 week Radiotherapy No prior radiotherapy 50 % pelvis Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>